货号 (SKU)

包装规格

是否现货

价格

数量

Ab170550-100μg

100μg

现货

Ab170550-1mg

1mg

现货

Ab170550-5mg

5mg

现货

Ab170550-10mg

10mg

期货

基本信息

产品名称	Sutimlimab (anti-C1s), 补体 C1s 抗体
别名	苏替米单抗（抗 C1s）
英文别名	C1 esterase \| Complement component 1 subcomponent s \| EC 3.4.21.42
规格或纯度	无载体, 重组, ExactAb™, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	C1S
应用	ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt
种属反应性	人(Human)
偶联	Unconjugated
作用类型	抑制剂
作用机制	补体 C1s 抗体

产品属性

抗体类型	Primary antibody
克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG4SP
轻链亚型	kappa
SDS-PAGE	27.4 kDa (Light Chain) & 51.7 kDa (Heavy Chain), under reducing conditions; 177.1 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	2049079-64-1
分子类型	抗体

图片

ELISA: Sutimlimab (anti-C1s) (Ab170550)

Sutimlimab (anti-C1s) (Ab170550) - ELISA
Immobilized huC1s-chis at 2 μg/mL can bind Sutimlimab (anti-C1s) (Ab170550) with the EC₅₀ of 6.16 ng/mL.

SEC: Sutimlimab (anti-C1s) (Ab170550)

Sutimlimab (anti-C1s) (Ab170550) - SEC
The purity of Sutimlimab (anti-C1s) (Ab170550) is more than 95% verified by HPLC.

关联靶点（人）

C1S Tclin 补体 C1s 亚成分(Complement C1s subcomponent) (0 活性数据)

点击查看靶蛋白信息： C1S

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

质量标准

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F0202852	分析证书	24-02-23	Ab170550
ZJ24F0202851	分析证书	24-02-23	Ab170550
ZJ24F0202850	分析证书	24-02-23	Ab170550

参考文献

1. Wahrmann M, Mühlbacher J, Marinova L, Regele H, Huttary N, Eskandary F, Cohen G, Fischer GF, Parry GC, Gilbert JC et al.. (2017) Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study.. Am J Transplant, 17 (9): (2300-2311). [PMID:28251805]
2. Mühlbacher J, Jilma B, Wahrmann M, Bartko J, Eskandary F, Schörgenhofer C, Schwameis M, Parry GC, Gilbert JC, Panicker S et al.. (2017) Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.. Transplantation, 101 (10): (2410-2418). [PMID:28926521]
3. Eskandary F, Jilma B, Mühlbacher J, Wahrmann M, Regele H, Kozakowski N, Firbas C, Panicker S, Parry GC, Gilbert JC et al.. (2018) Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.. Am J Transplant, 18 (4): (916-926). [PMID:28980446]
4. Nikitin PA, Rose EL, Byun TS, Parry GC, Panicker S. (2019) C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro.. J Immunol, 202 (4): (1200-1209). [PMID:30635392]
5. Subasinghe NL, Travins JM, Ali F, Huang H, Ballentine SK, Marugán JJ, Khalil E, Hufnagel HR, Bone RF, DesJarlais RL et al.. (2006) A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s.. Bioorg Med Chem Lett, 16 (8): (2200-4). [PMID:16460935]
6. Subasinghe NL, Ali F, Illig CR, Jonathan Rudolph M, Klein S, Khalil E, Soll RM, Bone RF, Spurlino JC, DesJarlais RL, Crysler CS, Cummings MD, Morris PE, Kilpatrick JM, Sudhakara Babu Y.. (2004) A novel series of potent and selective small molecule inhibitors of the complement component C1s.. Bioorg Med Chem Lett, 14 (12): (3043-3047). [PMID:15149641] [10.1016/j.bmcl.2004.04.034]
7. Travins JM, Ali F, Huang H, Ballentine SK, Khalil E, Hufnagel HR, Pan W, Gushue J, Leonard K, Bone RF, Soll RM, DesJarlais RL, Crysler CS, Ninan N, Kirkpatrick J, Cummings MD, Huebert N, Molloy CJ, Gaul M, Tomczuk BE, Subasinghe NL.. (2008) Biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s.. Bioorg Med Chem Lett, 18 (5): (1603-1606). [PMID:18242991] [10.1016/j.bmcl.2008.01.064]
8. Meneyrol J, Follmann M, Lassalle G, Wehner V, Barre G, Rousseaux T, Altenburger JM, Petit F, Bocskei Z, Schreuder H, Alet N, Herault JP, Millet L, Dol F, Florian P, Schaeffer P, Sadoun F, Klieber S, Briot C, Bono F, Herbert JM.. (2013) 5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.. J Med Chem, 56 (23): (9441-9456). [PMID:24175584] [10.1021/jm4005835]
9. Buckley BJ, Aboelela A, Minaei E, Jiang LX, Xu Z, Ali U, Fildes K, Cheung CY, Cook SM, Johnson DC, Bachovchin DA, Cook GM, Apte M, Huang M, Ranson M, Kelso MJ.. (2018) 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.. J Med Chem, 61 (18): (8299-8320). [PMID:30130401] [10.1021/acs.jmedchem.8b00838]
10. Illy, C C, Thielens, N M NM, Gagnon, J J and Arlaud, G J GJ.. (1991) Effect of lactoperoxidase-catalyzed iodination on the Ca(2+)-dependent interactions of human C1s. Location of the iodination sites.. Biochemistry, (23): [PMID:1854725]
11. Hess, D D, Schaller, J J and Rickli, E E EE.. (1991) Identification of the disulfide bonds of human complement C1s.. Biochemistry, (19): [PMID:2007122]
12. Thielens, N M NM, Van Dorsselaer, A A, Gagnon, J J and Arlaud, G J GJ.. (1990) Chemical and functional characterization of a fragment of C1-s containing the epidermal growth factor homology region.. Biochemistry, (10): [PMID:2141278]
13. Kusumoto, H H, Hirosawa, S S, Salier, J P JP, Hagen, F S FS and Kurachi, K K.. (1988) Human genes for complement components C1r and C1s in a close tail-to-tail arrangement.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2459702]
14. Tosi, M M, Duponchel, C C, Meo, T T and Couture-Tosi, E E.. (1989) Complement genes C1r and C1s feature an intronless serine protease domain closely related to haptoglobin.. Journal of molecular biology, (20): [PMID:2553984]
15. Tosi, M M, Duponchel, C C, Meo, T T and Julier, C C.. (1987) Complete cDNA sequence of human complement Cls and close physical linkage of the homologous genes Cls and Clr.. Biochemistry, (29): [PMID:2831944]
16. Spycher, S E SE, Nick, H H and Rickli, E E EE.. (1986) Human complement component C1s. Partial sequence determination of the heavy chain and identification of the peptide bond cleaved during activation.. European journal of biochemistry, (1): [PMID:3007145]
17. Mackinnon, C M CM, Carter, P E PE, Smyth, S J SJ, Dunbar, B B and Fothergill, J E JE.. (1987) Molecular cloning of cDNA for human complement component C1s. The complete amino acid sequence.. European journal of biochemistry, (15): [PMID:3500856]
18. Carter, P E PE, Dunbar, B B and Fothergill, J E JE.. (1983) The serine proteinase chain of human complement component C1s. Cyanogen bromide cleavage and N-terminal sequences of the fragments.. The Biochemical journal, (1): [PMID:6362661]
19. Rossi, V V and 6 more authors.. (1995) Structure of the catalytic region of human complement protease C1s: study by chemical cross-linking and three-dimensional homology modeling.. Biochemistry, (6): [PMID:7779774]
20. Endo, Y Y and 7 more authors.. (1998) Two lineages of mannose-binding lectin-associated serine protease (MASP) in vertebrates.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:9794427]
21. Gaboriaud, C C, Rossi, V V, Bally, I I, Arlaud, G J GJ and Fontecilla-Camps, J C JC.. (2000) Crystal structure of the catalytic domain of human complement c1s: a serine protease with a handle.. The EMBO journal, (17): [PMID:10775260]
22. Dragon-Durey, M A MA and 7 more authors.. (2001) Molecular basis of a selective C1s deficiency associated with early onset multiple autoimmune diseases.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:11390518]
23. Rossi, V V and 5 more authors.. (2001) Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and -2.. The Journal of biological chemistry, (2): [PMID:11527969]
24. Gregory, Lynn A LA, Thielens, Nicole M NM, Arlaud, Gérard J GJ, Fontecilla-Camps, Juan Carlos JC and Gaboriaud, Christine C.. (2003) X-ray structure of the Ca2+-binding interaction domain of C1s. Insights into the assembly of the C1 complex of complement.. The Journal of biological chemistry, (22): [PMID:12788922]
25. Liu, Tao T and 6 more authors.. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.. Journal of proteome research, [PMID:16335952]
26. Kapferer-Seebacher, Ines I and 39 more authors.. (2016) Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S, which Encode Subcomponents C1r and C1s of Complement.. American journal of human genetics, (3): [PMID:27745832]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Sutimlimab (anti-C1s), 补体 C1s 抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Sutimlimab (anti-C1s), 补体 C1s 抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器